INDV News & Events

Indivior Pharmaceuticals will present one new scientific poster and collaborated with VA Tech on a second poster which will be presented at the American Society of Addiction Medicine Annual Conference, held April 23-26, 2026, in San Diego, California. The data add to the growing body of evidence evaluating extended-release buprenorphine, a monthly injectable commercially available as SUBLOCADE, in supporting meaningful outcomes for people living with OUD, including overdose-related outcomes and broader indicators associated with recovery. Impact of OAT in individuals with OUD who experienced an overdose in Ontario, Canada: This retrospective nested case-control study used Ontario administrative health data of more than 45,000 patients with OUD to evaluate associations between MOUD treatments, including SUBLOCADE, transmucosal buprenorphine, methadone, and sustained-release oral morphine and the risk of opioid-related fatal and non-fatal overdose. Most overdose events occurred off treatment: Patients with higher MOUD coverage experienced less non-fatal and fatal overdose compared to those with lower MOUD coverage. Buprenorphine-based MOUD significantly reduced overdose risk: Of all MOUD, SUBLOCADE accounted for the smallest proportion of non-fatal and fatal OD events compared to no treatment. Both SUBLOCADE and TM-BUP had the lowest odds of all MOUD odds of non-fatal and fatal overdose versus no MOUD. Study limitations include potential misclassification in administrative data, incomplete or inaccurate capture of opioid-related OD events and OAT use, and absence of a direct measure of OAT adherence. Associations between remission from opioid use disorder and treatment-relevant outcomes: Provisional findings from the Remission from OUD as a Treatment Endpoint followed 443 participants within 0-3 months of starting treatment with SUBLOCADE for up to 12 months to understand how OUD remission relates to treatment-relevant and recovery-related outcomes. Remission as an indicator of improved outcomes: Individuals entering the study in remission for 3-months indicated lower craving, lower withdrawal, lower pain, better quality of life, and lower rates of unemployment than those not in remission. Complete abstinence may neither be sufficient nor necessary: Opioid misuse and OUD remission are not always consistent; an individual may abstain from opioid misuse while not yet meeting criteria for 3-month remission, underscoring the importance of remission as a clinically meaningful treatment endpoint. One study limitation is that participants entered at varying BUP-XR treatment durations, so study entry does not align with treatment initiation.

Indivior Pharmaceuticals announced its intention to offer, subject to market and other conditions, $400,000,000 aggregate principal amount of convertible senior notes due 2031 in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Indivior also expects to grant the initial purchasers of the notes a 30-day option to purchase up to an additional $60,000,000 principal amount of notes. The notes will be senior, unsecured obligations of Indivior, will accrue interest payable semi-annually in arrears and will mature on March 15, 2031, unless earlier repurchased, redeemed or converted. Noteholders will have the right to convert their notes in certain circumstances and during specified periods. Indivior will settle conversions by paying or delivering cash and, if applicable, shares of its common stock.

Indivior Pharmaceuticals announced findings from a new real-world evidence, retrospective observational study published in Frontiers in Public Health showing that adherence to Sublocade, a monthly injectable, is associated with meaningfully lower healthcare utilization and medical costs among commercially insured patients with opioid use disorder. These outcomes were more favorable compared to both patients adherent to other medications for OUD and to those who were nonadherent to MOUD. "These data highlight the potential of long-acting injectable buprenorphine treatment to improve care continuity for people living with OUD and reduce the need for acute, high-cost healthcare services," said Christian Heidbreder, Ph.D., Chief Scientific Officer at Indivior.

"We delivered on our financial commitments in 2025, growing total SUBLOCADE net revenue 13% and adjusted EBITDA 20%, while positioning Indivior for acceleration in 2026," said Ryan Preblick, Chief Financial Officer. "In 2026, we expect to deliver SUBLOCADE dispense unit growth in the mid-teens with operating expenses that will not exceed $450 million, and generate approximately $300 million in cash flow from operations. Our capital deployment priorities include managing our debt, opportunistically deploying our new $400 million share repurchase program and evaluating business development opportunities as we earn our way to Phase III of the Indivior Action Agenda - Breakout."